PPT-Different Stroke for Different Folks: Outcomes in Intervent

Daniel S Bennett MD DABPM Denver Colorado USA Any tool is a weapon if you hold it right Ani Difranco b 1970 Case Acute LLE L5 Radiculopathy 3 2 y HM Ht 1702cm Wt 645kg. Old folks allow their bellies to jig gle like slow tambourines The hollers rise up and spill over any way they want When old folks laugh they free the world They turn slowly slyly knowing the best and worst of remembering Saliva glistens in the cor MAYA ANGELOU. Born on April 4th, 1928, in St. Louis, Missouri, Dr. Angelou was raised in St. Louis and Stamps, Arkansas. In Stamps, Dr. Angelou experienced the brutality of racial discrimination, but she also absorbed the unshakable faith and values of traditional African-American family, community, and culture. . What is PCORI?. PROSPER is funded by PCORI . PCORI . =Patient Centered Outcomes . . Research Institute. Nonprofit organization established . . by the Affordable Care Act in 2010. PCORI’s Mission. Professor Malcolm Sperrin. Royal Berkshire Hospital. Drivers and Considerations. Ageing population. Greater range of treatments. Improved diagnostic tools. Greater expectations. Crikey factors. Equipment capital cost. ESO Conference. Glasgow, Scotland. April 17, 2015. J Mocco. 1. , Osama Zaidat. 2. , . Rüdiger. von Kummer. 3. , Albert Yoo. 4. , Rishi Gupta. 5. , Demetrius Lopes. 6. , Don . Frei. 7. , . Pooja. Khatri. MD. , . Associate . Professor of Emergency . Medicine Stanford . University School of Medicine. David Tong, MD. , . Director, Telemedicine Network, California Pacific Medical Center. George Oldham, MD. FDA-Mandated CV Safety Trials. 1. TECOS. (Trial Evaluating Cardiovascular Outcomes with Sitagliptin). Clinical Outcomes with Antihyperglycemic Agents. 2. Clinical Outcomes with Sitagliptin. Study Design. Network Effort (SHINE) Trial . NIH-NINDS . U01 . NS069498. An Overview of SHINE. Contents. Background. Trial Overview. Treatment Groups. Outcomes. I-SPOT Ancillary Study. SHINE Background. Most animal stroke studies show that hyperglycemia at stroke onset leads to worse outcomes than . CVOTs. 1. FDA CVOT Guidance—2008. Timeline of Major Diabetes. Outcomes Trials. 2. Blue. = Intensive vs standard control using same set of glucose-lowering agent(s). Purple. = Intensive control with a specific agent vs standard care. Increase partner knowledge of HDSP priorities and strategies Increase physician knowledge of clinical guidelines Increase knowledge of signs and symptoms of stroke and of the need to call 9-1-1 In Resuming Warfarin Treatment After . Hemorrhagic Stroke or . Traumatic . Intracranial. Hemorrhage in Patients With Atrial Fibrillation. JAMA Internal Medicine . 2017;177(4):563-570. . DOI: . 10.1001/jamainternmed.2016.9369. e-CEA is superior to c-CEA without patch angioplasty. Our findings emphasize the importance of patch angioplasty in c-CEA and demonstrate that this technique is commensurate to e-CEA.. BACKGROUND. CONCLUSION. lesions. The hazard . was highest . with CABG in the first 30 . days with better outcomes with PCI; between . 30 days and . 5 . years, . outcomes were inferior . with PCI compared with . CABG. CABG. (n = 592). What effect does glycemic control with insulin have on these complications?. None. . Insulin does not improve mortality rates/neurological outcomes after stroke. Why do we care?. Stroke is the 5. th.